newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Devdiscourse
Apothecon Group has announced Shyamakant Giri as the new Chief Executive Officer, effective May 11, 2026.
Shyamakant Giri will become CEO of Apothecon Group on May 11, 2026.
KEY POINTS
Giri previously served as CEO at Gland Pharma Limited before joining Apothecon Group.
Apothecon Group is planning global expansion focusing on complex generic drugs under Giri's leadership.
Everstone Capital supports Apothecon Group and is a major investor in high-growth sectors.
Apothecon Group has announced Shyamakant Giri as the new Chief Executive Officer, effective May 11, 2026. With a base in Vadodara, India, Giri is set to drive the company's forthcoming growth and strategic expansion phases.
Supported by Everstone Capital, a key player in investment across high-growth sectors, Apothecon Group specializes in pharmaceutical and healthcare market solutions. Mr. Giri, with over 25 years in leadership roles within pharmaceuticals and healthcare, joins from Gland Pharma Limited where he was CEO.
Giri expressed his enthusiasm, stating that the group's development, manufacturing, and marketing strengths in complex generic drugs provide a robust platform for further growth. The company aims to leverage his expertise in their bid to strengthen their global marketplace presence.
(With inputs from agencies.)